JOVANA
Library Glossary Getting Started Three Levels Fields How it works Mission
Join the mission
All guides

Getting Chirality Right

Most drugs are single enantiomers, and the wrong one can be inactive or even harmful. Learn why chirality matters biologically, and the three practical routes to a single enantiomer: the chiral pool, asymmetric synthesis, and resolution.

Why one mirror image, not both

A chiral molecule and its mirror image are enantiomers — identical in every flat property but non-superimposable, like left and right hands. Because a protein's active site is itself chiral, molecular recognition distinguishes the two: one enantiomer may bind tightly and the other barely at all. Often only one enantiomer carries the desired activity; the other can be inert, or worse, hit an off-target and cause toxicity. That is why regulators expect a clear rationale for using a racemate rather than a single enantiomer.

Three routes to a single enantiomer

The first route is the [[chiral-pool|chiral pool]]: start from a cheap, naturally single-enantiomer molecule — an amino acid, a sugar, a terpene — and carry its chirality through your synthesis. If a building block already has the stereocenter you need in the right configuration, you get enantiopurity essentially for free. The limitation is availability: nature supplies certain configurations abundantly and their mirror images rarely.

The second route is [[asymmetric-synthesis|asymmetric synthesis]]: create the stereocenter selectively using a chiral catalyst, reagent, or auxiliary — for example asymmetric hydrogenation, organocatalysis, or an enzyme. Done well, it builds either enantiomer on demand from achiral starting materials. The cost is method development: finding the catalyst and conditions that give high enantiomeric excess (ee) can take real effort.

The third route is resolution: make the racemate, then separate the enantiomers. Classical resolution forms diastereomeric salts with a chiral acid or base that can be crystallised apart; chiral chromatography (chiral SPC/HPLC) separates them physically and is the workhorse for fast early-stage delivery of both enantiomers for testing. Resolution wastes up to half the material, so it is convenient early but rarely the answer at scale.

Choosing a strategy in practice

There is no single right answer — the best strategy depends on where you are in the project. Early, you value speed and getting both enantiomers in hand to test; later, when one enantiomer is the committed candidate, you value a clean, scalable route. A sensible default progression looks like this.

  1. Early on, when you just need both enantiomers to test, make the racemate and separate by chiral chromatography — fastest path to data.
  2. If a chiral-pool building block matches your needed stereocenter, use it — enantiopurity for almost no extra work.
  3. Once the single enantiomer is the committed candidate, invest in asymmetric synthesis to give a clean, scalable, low-waste route.
  4. Always measure ee (chiral HPLC) and assign absolute configuration before drawing SAR conclusions.